Acrivon Therapeutics, Common Stock Last Dividend Paid
| ACRV Stock | 7.45 0.01 0.13% |
Acrivon Therapeutics, Common fundamentals help investors to digest information that contributes to Acrivon Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Acrivon Stock. The fundamental analysis module provides a way to measure Acrivon Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acrivon Therapeutics, stock.
Acrivon | Last Dividend Paid |
Acrivon Therapeutics, Common Company Last Dividend Paid Analysis
Acrivon Therapeutics,'s Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Acrivon Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Acrivon Therapeutics, is extremely important. It helps to project a fair market value of Acrivon Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Acrivon Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acrivon Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acrivon Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Acrivon Dividend Paid And Capex Coverage Ratio
Dividend Paid And Capex Coverage Ratio |
|
Based on the recorded statements, Acrivon Therapeutics, Common has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Acrivon Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Acrivon Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Acrivon Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Acrivon Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 52.57 M | ||||
| Shares Outstanding | 31.14 M | ||||
| Shares Owned By Insiders | 22.38 % | ||||
| Shares Owned By Institutions | 75.97 % | ||||
| Number Of Shares Shorted | 1.11 M | ||||
| Price To Book | 1.20 X | ||||
| EBITDA | (59.85 M) | ||||
| Net Income | (60.39 M) | ||||
| Total Debt | 4.64 M | ||||
| Book Value Per Share | 5.38 X | ||||
| Cash Flow From Operations | (42.64 M) | ||||
| Short Ratio | 15.38 X | ||||
| Earnings Per Share | (2.66) X | ||||
| Target Price | 21.56 | ||||
| Number Of Employees | 58 | ||||
| Market Capitalization | 236.01 M | ||||
| Total Asset | 138.26 M | ||||
| Retained Earnings | (116.42 M) | ||||
| Working Capital | 116.39 M | ||||
| Net Asset | 138.26 M |
About Acrivon Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acrivon Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.